4.7 Article

Effect of RecA inactivation on quinolone susceptibility and the evolution of resistance in clinical isolates of Escherichia coli

期刊

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
卷 76, 期 2, 页码 338-344

出版社

OXFORD UNIV PRESS
DOI: 10.1093/jac/dkaa448

关键词

-

资金

  1. Instituto de Salud Carlos III, Ministerio de Economia y Competitividad
  2. European Development Regional Fund 'A way to achieve Europe' ERDF, Spanish Network for Research in Infectious Diseases [REIPI RD12/0015, RD16/0016]
  3. Plan Nacional de I+D+i 2013-2016
  4. Instituto de Salud Carlos III, Subdireccion General de Redes y Centros de Investigacion Cooperativa, Ministerio de Economia, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [PI14/00940, PI17/01501, AC16/00072, RD16/0016/0001, REIPI RD16/0016/0009]
  5. European Development Regional Fund 'A way to achieve Europe', Operative Programme Intelligent Growth 2014-2020

向作者/读者索取更多资源

RecA inactivation leads to decreased fluoroquinolone resistance in Escherichia coli clinical isolates, especially in high-risk clone ST131. Inactivation of the SOS system results in a survival disadvantage for E. coli, reducing the development of quinolone resistance.
Background: SOS response suppression (by RecA inactivation) has been postulated as a therapeutic strategy for potentiating antimicrobials against Enterobacterales. Objectives: To evaluate the impact of RecA inactivation on the reversion and evolution of quinolone resistance using a collection of Escherichia coli clinical isolates. Methods: Twenty-three E. coli clinical isolates, including isolates belonging to the high-risk clone ST131, were included. SOS response was suppressed by recA inactivation. Susceptibility to fluoroquinolones was determined by broth microdilution, growth curves and killing curves. Evolution of quinolone resistance was evaluated by mutant frequency and mutant prevention concentration (MPC). Results: RecA inactivation resulted in 2-16-fold reductions in fluoroquinolone MICs and modified EUCAST clinical category for several isolates, including ST131 clone isolates. Growth curves and time-kill curves showed a clear disadvantage (up to 10 Log(10) cfu/mL after 24 h) for survival in strains with an inactivated SOS system. For recA-deficient mutants, MPC values decreased 4-8-fold, with values below the maximum serum concentration of ciprofloxacin. RecA inactivation Led to a decrease in mutant frequency (>= 10(3)-fold) compared with isolates with unmodified SOS responses at ciprofloxacin concentrations of 4xMIC and 1 mg/L. These effects were also observed in ST131 clone isolates. Conclusions: While RecA inactivation does not reverse existing resistance, it is a promising strategy for increasing the effectiveness of fluoroquinolones against susceptible clinical isolates, including high-risk clone isolates.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据